Sugi Predict

Sugi Predict / Targets / PSMB8

PSMB8

Proteasome subunit beta type-8 · P28062 · PSMB8 on Sugi Atlas →

52,060 patent compounds predicted against PSMB8, 31,334 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL605949 SCHEMBL605949 0.54 15/20
SCHEMBL97140 SCHEMBL97140 1.00 14/20
SCHEMBL459541 SCHEMBL459541 0.68 12/20
SCHEMBL607010 SCHEMBL607010 0.56 12/20
SCHEMBL464441 SCHEMBL464441 0.54 12/20
SCHEMBL464435 SCHEMBL464435 0.54 12/20
SCHEMBL606932 SCHEMBL606932 0.53 12/20
SCHEMBL606926 SCHEMBL606926 0.52 12/20
SCHEMBL606344 SCHEMBL606344 0.51 12/20
SCHEMBL606616 SCHEMBL606616 0.51 12/20
SCHEMBL118671 SCHEMBL118671 1.00 11/20
2-Mercaptobenzothiazole 2-Mercaptobenzothiazole (SCHEMBL408087) 1.00 11/20
SCHEMBL234139 SCHEMBL234139 0.71 11/20
SCHEMBL607035 SCHEMBL607035 0.61 11/20
SCHEMBL605158 SCHEMBL605158 0.59 11/20
SCHEMBL606315 SCHEMBL606315 0.59 11/20
SCHEMBL464494 SCHEMBL464494 0.56 11/20
SCHEMBL464427 SCHEMBL464427 0.55 11/20
SCHEMBL464464 SCHEMBL464464 0.55 11/20
SCHEMBL605822 SCHEMBL605822 0.54 11/20

Clinical trials — most relevant to PSMB8 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease PHASE4UNKNOWN
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer PHASE2COMPLETED
Colchicine for Amyotrophic Lateral Sclerosis PHASE2COMPLETED
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors PHASE2COMPLETED
MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma PHASE2WITHDRAWN
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma PHASE2WITHDRAWN
Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer PHASE2COMPLETED
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma PHASE2COMPLETED
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy PHASE2NOT_YET_RECRUITING
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy PHASE2ACTIVE_NOT_RECRUITING
Bortezomib in Treating Patients With Mantle Cell Lymphoma PHASE2COMPLETED
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma PHASE1COMPLETED
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer PHASE1COMPLETED
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma PHASE1COMPLETED
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma PHASE1UNKNOWN
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors PHASE1COMPLETED
Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery PHASE1COMPLETED
GO-203-2C + Bortezomib For Relapsed Or Refractory MM PHASE1WITHDRAWN
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS) nanUNKNOWN
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment nanUNKNOWN
Cardiovascular Complications of Carfilzomib Treatment nanUNKNOWN
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
The Pathophysiology of Bortezomib Induced Peripheral Neuropathy nanUNKNOWN
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT) nanUNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Progressive Familial Intrahepatic Cholestasis in Indian Children - Establishing an Indian PFIC Registry nanUNKNOWN
Muscle Wasting in Cancer (MWIC) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PSMB8 binder may also engage these)

ProteinNameSimilarity
P28064 — 1.000 P28064 →
Q3T112 — 1.000 Q3T112 →
Q5W416 — 1.000 Q5W416 →
P28063 — 1.000 P28063 →
P28075 — 0.999 P28075 →
O55234 — 0.997 O55234 →
Q5R8S2 — 0.995 Q5R8S2 →
P30656 — 0.994 P30656 →
Q54BC8 — 0.994 Q54BC8 →
PSMB7 Proteasome subunit beta type-7 0.994 landscape →
PSMB5 Proteasome Macropain subunit MB1 0.994 landscape →
P30655 — 0.994 P30655 →
Q32KL2 — 0.993 Q32KL2 →
P70195 — 0.992 P70195 →
O24361 — 0.992 O24361 →
A1XQU1 — 0.991 A1XQU1 →
Q4KM35 — 0.989 Q4KM35 →
Q9LIP2 — 0.989 Q9LIP2 →
Q5REN2 — 0.989 Q5REN2 →
Q2TBP0 — 0.989 Q2TBP0 →
Q3T0T1 — 0.988 Q3T0T1 →
Q09841 — 0.988 Q09841 →
Q9XUV0 — 0.988 Q9XUV0 →
Q3T0X5 — 0.988 Q3T0X5 →
O23717 — 0.988 O23717 →
PSMA1 Proteasome subunit alpha type-1 0.987 landscape →
P93395 — 0.987 P93395 →
Q8LD27 — 0.987 Q8LD27 →
P38624 — 0.987 P38624 →
O23712 — 0.986 O23712 →